で公開中です！詳しく見る

Zura Bio

ZURA

時価総額 $3.72億

3.88 USD

-0.40

9.35%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

3.93

+0.05

1.29%

1日

-9.35%

5日間

-3%

1か月

-15.84%

3か月

-26.1%

6か月

-32.05%

年初来

-30.09%

1年

13.12%

5年間

-60.45%

10年間

-60%

概要： Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

従業員数： 40

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

Zura Bio to Participate in the Cantor Global Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference: Cantor Global Healthcare Conference Location: New York, NY Fireside chat: Wednesday, September 9, 2026, at 9.

Zura Bio to Participate in the Cantor Global Healthcare Conference

ニュートラル

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These.

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ニュートラル

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. “The second quarter was marked by strong execution across our tibulizumab programs, with enrollment now com.

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

ポジティブ

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy

On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy across severe autoimmune diseases.

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy

ニュートラル

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced several tibulizumab program updates. Zura has completed enrollment of the Phase 2 TibuSHIELD trial of tibulizumab in adults with HS. The TibuSHIELD trial exceeded the target enrollment, with 247 participants.

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ニュートラル

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on May 13, 2026, the Company granted an inducement award consisting of an option to purchase up to 600,000 Class A Ordinary Shares (the “Option”) to Muzammil Mustufa, the Company's new Ch.

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ニュートラル

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts. Mr. Mustufa brings.

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

ニュートラル

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “We entered the second quarter with a strengthened balance sheet and strengthened team, reflecting growing.

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ニュートラル

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on April 30, 2026, the Company granted inducement awards consisting of options to purchase up to 615,160 Class A Ordinary Shares (the “Options”) to eight newly hired employees. These awar.

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ニュートラル

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025, and provided recent corporate updates. “2025 was a year of strong execution for Zura, marked by meaningful progress across our Phase 2 programs and.

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています